European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
Letermovir for the compassionate therapeutic use of cytomegalovirus infection.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schubert Lorenz, Fisecker Lisa, Thalhammer Florian, Burgmann Heinz, Steininger Christoph
Аннотация
PURPOSE: Data on the efficacy, dosing and safety of letermovir for the compassionate therapeutic use of CMV infections are limited.
METHODS: Clinical and virological efficacy of letermovir was assessed in a retrospective single-centre study of patients who received letermovir for the compassionate therapeutic use of CMV infections.
RESULTS: Letermovir initiation yielded prompt treatment response in 7 out of 9 patients (77.7%).
CONCLUSION: Letermovir may be an effective and well tolerated option in the compassionate treatment of CMV infections, although recurrence of CMV and emergence of resistance may be issues.
METHODS: Clinical and virological efficacy of letermovir was assessed in a retrospective single-centre study of patients who received letermovir for the compassionate therapeutic use of CMV infections.
RESULTS: Letermovir initiation yielded prompt treatment response in 7 out of 9 patients (77.7%).
CONCLUSION: Letermovir may be an effective and well tolerated option in the compassionate treatment of CMV infections, although recurrence of CMV and emergence of resistance may be issues.